Exchange: NASDAQ·Updated 07:30 PM EST

APMD Apnimed Inc.

$15.81
$0.05
(0.32%)
Today
Closed $15.86
$0.055
(0.35%)
After Hours
EarningsNov 11
Mkt Cap$658.18M
Vol378,259.00

About APMD

Apnimed, Inc. operates as a clinical-stage company. It engages in the discovery, development, and commercialization of oral therapies for sleep-related breathing diseases. The company was founded by Lawrence G. Miller, Barry Wohl and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA.
57

Bullish Sentiment

How do you feel about APMD?

SBL71
$APMD $14 on deck. With low volume and nothing material until 2027 Q1 its raft afloat in dead water.
1
Merlintrader
Apnimed $APMD posted Phase 3 LunAIRo AD109 efficacy numbers on the trial registry. At 6 months, AHI changed -3.88 on AD109 vs +0.21 on placebo, a -4.08 difference (p<0.001). Shares closed at $15.40 on Monday, below the SMA50, RSI 32. More details in our hub. Not investment advice.
1
Merlintrader
Apnimed $APMD posted Phase 3 LunAIRo AD109 results on the trial registry. The completed study of AD109 versus placebo in obstructive sleep apnea enrolled 660 patients. Shares closed at $15.40 on Monday, below the SMA50, RSI 39. More details in our hub. Not investment advice.
1
Merlintrader
📅 CATALYST REMINDER | $APMD October 20, 2026 — Clinical Data Presentation AD109 analyses from the Phase 3 SynAIRgy and LunAIRo programs will be presented at CHEST 2026. These are follow-up analyses, not a new pivotal readout. More details in our hub. #APMD #Biotech #CHEST2026

Advertisement|Remove ads.